Sunitinib in solid tumors

  title={Sunitinib in solid tumors},
  author={Hui Kong Gan and Bo{\vs}tjan {\vS}eruga and Jennifer J. Knox},
  journal={Expert Opinion on Investigational Drugs},
  pages={821 - 834}
  • H. GanB. ŠerugaJ. Knox
  • Published 25 May 2009
  • Medicine, Biology, Chemistry
  • Expert Opinion on Investigational Drugs
Background: Until recently, few treatments were available for renal cell carcinoma (RCC) and gastrointestinal stromal tumors (GIST). Several targeted agents inhibiting key pathogenetic pathways have since been developed for RCC (sunitinib, sorafenib, bevacizumab, temsirolimus, everolimus) and GIST (imatinib, sunitinib). Sunitinib is a multi-kinase inhibitor of VEGFR-2, PDGFR (α,β), FLT-3, KIT, CSF-1 and RET. Objective: To summarize the literature regarding the structure, pharmacokinetics… 

The potential of sunitinib as a therapy in ovarian cancer

Although clinical Phase II trials on the use of sunitinib in the treatment of OC demonstrated an acceptable profile of AEs, a greater comprehension of the toxicity of this compound is recommended.

Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies

Regorafenib is the only one to have demonstrated efficacy in this setting in a randomized, phase 3 trial, and has also shown promising efficacy in patients with HCC who progressed on nivolumab, which was recently granted approval by the FDA, although larger confirmative trials may be considered.

Sunitinib for metastatic renal cell carcinoma.

This article is an in-depth review of the mechanism of action of sunitinib, rationale for dose and schedule, toxicity and clinical efficacy, and other targeted therapies and treatment combinations for renal cell carcinoma.

Critical Appraisal of Ramucirumab (IMC-1121B) for Cancer Treatment: From Benchside to Clinical Use

Ramucirumab, a fully humanized monoclonal antibody specifically directed against the extracellular domain of the receptor, administered intravenously every 2 or 3 weeks, is emerging as a novel antiangiogenic opportunity.

Oral administration of sunitinib malate for long-term survival of a patient with multiple lung metastases from renal leiomyosarcoma

A patient with lung metastases from renal leiomyosarcoma who responded favorably to sunitinib after the failure of conventional chemotherapy is reported, indicating that this small-molecule drug might be an effective treatment for renal leIomyosARcoma, especially when conventional chemotherapy fails.

Evaluation of Safety and Efficacy of Salvage Therapy With Sunitinib, Docetaxel (Tyxan) and Cisplatinum Followed by Maintenance Vinorelbine for Unresectable/Metastatic Nonsmall Cell Lung Cancer

Sunitinib combined with chemotherapy shows promise and warrants further investigation.

Safety of sunitinib in patients with renal cell carcinoma following nephrectomy

In the adjuvant setting, even if the toxicity profile of sunitinib does not differ significantly from that in the metastatic setting, the importance of the dose intensity and, thus, exposure has been emphasized and management of the adverse effects of sun itinib remains critical.

Chemoresponse assay for evaluating response to sunitinib in primary cultures of breast cancer

In vitro chemoresponse assay assessment is an effective tool for evaluating sunitinib sensitivity in cultured cell lines as well as ex vivo breast cancer samples and evaluating vendors’ supply of the compound.



Sunitinib: from rational design to clinical efficacy.

  • L. ChowS. Eckhardt
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
The clinical benchmarking of this small-molecule inhibitor of members of the split-kinase domain family of RTKs will lead to additional insights regarding the biology, potential biomarkers, and clinical utility of agents that target multiple signaling pathways in tumor, stromal, and endothelial compartments.

Phase 2 study of sunitinib in refractory thyroid cancer

This data indicates that sunitinib, has inhibitory activity against RET, VEGFR, and PDG FR, and thus has potential to be active in both DTC and MTC, and may help patients with refractory differentiated and medullary thyroid cancers.

Sunitinib in the management of gastrointestinal stromal tumours (GISTs).

  • T. HopkinsM. MarplesD. Stark
  • Medicine, Biology
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • 2008

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.

Sunitinib has promising single-agent activity in patients with recurrent NSCLC, with an ORR similar to that of currently approved agents and an acceptable safety profile, and further evaluation in combination with other targeted agents and chemotherapy is warranted.

Activity of sunitinib in patients with advanced neuroendocrine tumors.

  • M. KulkeH. Lenz C. Fuchs
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
Sunitinib has antitumor activity in pancreatic neuroendocrine tumors; its activity against carcinoid tumors could not be definitively determined in this nonrandomized study.

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

  • B. RiniM. Michaelson D. George
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
Sunitinib has substantial antitumor activity in patients with bevacizumab-refractory mRCC and modulates circulating VEGF pathway biomarkers, and Baseline levels of sVEGFR-3 and VEGf-C may have potential utility as biomarkers of clinical efficacy in this setting.

Continuous daily dosing (CDD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: Results of a phase II trial

The current phase II study was designed to examine the clinical activity of CDD of SU in pts with advanced STS other than GIST, and the primary endpoint is ORR per arm based on RECIST.

Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC)

Thyroid function was evaluated prospectively in pts with advanced RCC on days l and 28 of each treatment cycle and the Kaplan-Meier method was used to construct curves for PFS and OS.

A phase II trial of sunitinib in patients with recurrent high-grade glioma

Sunitinib is a small molecule that inhibits the VEGFRs, FLT1, FLK1/KDR, PDGFR-a and -b, c-Kit, the FLT3 and RET kinases in high-grade gliomas.